Underweight CL with 15% trim at market, targeting 70-80% sizing on confirmed breakdown
The Underweight call is directionally correct — confirmed by the convergence of the Research Manager, the Aggressive Analyst, and the operating deleverage signal — but the execution discipline must be borrowed from the Neutral Analyst to avoid the two specific failure modes: (1) the 9/16 lesson's "trim at support is a costless option that expires worthless" trap, and (2) the 9/18 lesson's "structural break leaks alpha" failure on Hold. The synthesis that resolves both: trim at current market levels (where execution is guaranteed) rather than at the $90.58 target the trader proposed (where execution is contingent on a rally that may not materialize in a low-beta name with broken momentum). The 15% trim captures approximately 75% of the available bearish alpha while leaving 85% of the position to participate in any upside resolution from Q3 earnings and the Goldman-advised divestiture catalyst.
| Position | Action |
|---|---|
| Standard mandate — directional Underweight call with broken technicals and operating deleverage | Trim 15% at market, reducing to ~85% of equal-weight benchmark |
| Confirmed close below $85.50 on volume >5M shares | Execute second tranche of 5-10% trim, reduce to 70-75% of equal-weight benchmark |
| Confirmed close above $90.58 with positive MACD histogram AND RSI >50 | Upgrade to Hold at 80-85% of benchmark, reassess sizing |
| Confirmed close above $87.94 with RSI >50 AND MACD histogram turning positive | Add back half the trimmed size, upgrade to Hold |
| Pullback to $82-84 zone with RSI <30 + bullish divergence on daily | Scale back into full benchmark weight |
| Confirmed close below $84.50 with volume >5M | Exit residual entirely, wait for structural floor defense |
| Income-only mandates — position exists to harvest 2.46% dividend yield and 5.2% FCF yield | Trim only 5-7%, reducing to ~93-95% of equal-weight benchmark |
Colgate-Palmolive's 11.2% correction from its February 2026 peak represents a routine, healthy pullback in a low-beta (β = 0.32) quality compounder, creating an asymmetric risk-reward entry with Q2 revenue accelerating to 4.9% YoY, gross margins expanding 150bps to 61.5%, and a strategic Goldman Sachs-advised portfolio divestiture providing a near-term catalyst—all supporting a BUY rating with $98-102 price target.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | 87.53 | bearish |
| 50 SMA | 90.58 | bearish |
| 200 SMA | 87.46 | neutral |
| RSI(14) | 40.35 | bearish |
| MACD | -1.15 | bearish |
| MACD Signal | -1.03 | bearish |
| MACD Histogram | -0.12 | neutral |
| BOLL Mid (20 SMA) | 88.75 | bearish |
| BOLL Upper | 92.18 | neutral |
| BOLL Lower | 85.33 | neutral |
| ATR(14) | 1.60 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed close above $90.58 (50 SMA) with positive MACD histogram AND RSI >50
Then: Upgrade to Hold at 80-85% of benchmark
Q2 2026 shows accelerating fundamentals with margin expansion—H1 net income comparison to prior year is misleading due to non-recurring tailwinds
↩ rebuts: “Bear's earnings plateau argument comparing apples to rotten apples with H1 2025”
EV: ~+13-17% (12-18 month price target of $98-102 from ~$87 current price) plus 2.46% dividend yield · concedes: The bear's technical analysis correctly identifies the stock is below both the 50 SMA ($90.58) and 200 SMA ($87.46); H1 2026 net income ($1,339M) is genuinely below H1 2025 ($1,486M); Forward P/E of 21x assumes recovery not yet fully visible in earnings; MACD histogram is negative at −0.12; An 11% decline does represent meaningful short-term drawdown even if routine
CL is a broken setup hiding behind quality branding—technical deterioration, operating margin contraction, premium valuation in a higher-for-longer rate regime, and structural competitive weakness create asymmetric downside risk to $82-85 versus limited upside to $98-102.
· concedes: Top-line revenue growth at 4.9% YoY is acceptable; Gross margin expansion of 150bps looks good on surface; FCF covers dividend 2.06x; Dividend yield of 2.46% is competitive for income investors; The bull's framework of 'consensus-fighter thinking' is intellectually coherent
→ vs conservative: Dividend King status and 131-year dividend record are not margin of safety—they are margin of risk when earnings are contracting and payout ratio is elevated
→ vs conservative: Three-year TSR of 26% and YTD up 12% is rearview mirror; trading September 2026 fundamentals show operating deleverage from ad spend acceleration not translating to operating leverage
→ vs conservative: 'Hold for compound' stance assumes next data point validates the bet; asymmetric risk is being priced in for it not to
→ vs neutral: 'Defensive demand intact' contradicts technicals: CL riding lower Bollinger Band, trading below key moving averages, marginal buyer not present
→ vs neutral: 'Wait for 200 SMA to reclaim' framing is incorrect—when price sits on 200 SMA and fails to reclaim, path of least resistance is to lose it, not bounce
→ vs neutral: 'Wait for Q3 print for clarity' is wrong approach—be OUT before Q3 print as setup is for earnings disappointment to validate bear case
→ vs neutral: HOLD posture inappropriate given 25x multiple on Dividend King with contested payout ratio, sitting on 200 SMA, into Fed hike, with EM exposure and catalyst calendar front-loaded against position
| VWMA (20-day) | 87.85 | bearish |
Support: 86.26 · 85.33 · 84.13 · 84.49 · 82.15 | Resistance: 87.53 · 88.75 · 90.58
CL is in a confirmed medium-term downtrend with price (87.05) trading below its 50 SMA (90.58) and 10 EMA (87.53), but only marginally below the 200 SMA (87.46) — the critical pivot level. The stock has declined approximately 11.2% from the late-February 2026 peak of ~98.15 over ~7 months. RSI is weak but not extreme at 40.35, and MACD is negative (-1.15) with a narrowing histogram (-0.12), suggesting momentum is bearish but decelerating. Bollinger Bands are wide (upper 92.18, lower 85.33) with price near the lower band, and ATR of 1.60 indicates moderate volatility (~1.8% of price). Volume profile shows an orderly distribution pattern with a notable spike of 10.84M on Sep-18, followed by elevated but stabilizing volume (~7.3–7.4M). The 200 SMA at 87.46 is the line in the sand — a daily close below ~85 would signal breakdown, while reclaim above 10 EMA (87.53) followed by 50 SMA (90.58) would mark trend reversal. Recommendation: HOLD with defensive bias; avoid bottom-fishing without confirmation.
Market Cap
$69.39 B
Price (implied)
~$87
52-Week High
$99.33
52-Week Low
$74.55
50-Day Moving Average
$90.75
200-Day Moving Average
$88.11
Beta
0.32
Dividend Yield
2.46%
P/E (TTM)
34.27x
Forward P/E
21.22x
PEG Ratio
1.57
2025 Revenue
$20,382M
2024 Revenue
$20,101M
2025 Gross Profit
$12,251M
2025 Gross Margin
60.1%
2025 Operating Income
$4,233M
2025 Operating Margin
20.8%
2025 Net Income
$2,132M
2025 Diluted EPS
$2.63
2025 Normalized EPS
~$3.48
2025 Normalized EBITDA
$4,885M
2025 Reported EBITDA
$3,956M
2025 Asset Impairment
$919M
2025 Total Unusual Items
$929M
2025 Cash & Equivalents
$1,288M
2025 Total Assets
$16,330M
2025 Total Liabilities
$15,965M
2025 Stockholders' Equity
$54M
2025 Tangible Book Value
($4,604M)
2025 Treasury Stock
($28,450M)
2025 Net Debt
$6,700M
2025 Total Debt
$8,554M
2025 Operating Cash Flow
$4,198M
2025 Capital Expenditure
$564M
2025 Free Cash Flow
$3,634M
2025 FCF CAGR (2022-2025)
25%
2025 FCF Yield
5.2%
2025 Dividends Paid
$1,823M
2025 Share Repurchases
$1,210M
2025 CapEx as % of Sales
2.8%
2025 Shareholder Return (Dividends + Buybacks)
~$3.0B/yr
Diluted Shares Outstanding
811.1M
Q2 2026 Revenue
$5,361M
Q2 2026 Revenue Growth YoY
4.9%
Q2 2026 Gross Margin
61.5%
Q2 2026 Operating Margin
19.0%
Q2 2026 Diluted EPS
$0.86
Q1 2026 Diluted EPS
$0.80
H1 2026 Net Income
$1,339M
H1 2025 Net Income
$1,486M
Annualized Run-Rate EPS
~$3.50
Implied P/E on Normalized EPS
~25.0x
Implied P/E on H1 2026 Annualized
~25.3x
Return on Assets (ROA)
15.84%
Return on Equity (ROE)
267.4%
Normalized Operating Margin
~22.5%
Profit Margin (TTM)
9.68%
Net Debt / EBITDA
~1.7x
Current Ratio
1.026x
Working Capital
($1,144M)
2026 Consensus Forward EPS
$4.10
Strengths
Concerns
Colgate-Palmolive (CL) presents a classic defensive consumer staples profile with iconic brands, very low beta (0.32), and a CapEx-light business model generating ~60% gross margins and ~21% operating margins. The company returned >70% of operating cash flow to shareholders in 2025 ($3.0B in dividends + buybacks), driving FCF from $1.86B to $3.63B over three years (25% CAGR). However, 2025 results were distorted by a $919M asset impairment that depressed net income 26% YoY to $2.13B, and normalizing yields EPS of ~$3.48 — making the TTM P/E of 34.27x appear artificially elevated. The rating of HOLD reflects that while Q2 2026 showed encouraging revenue acceleration (4.9% YoY) and margin expansion (61.5% gross margin), H1 2026 underlying earnings showed slight contraction versus the prior year, the valuation at ~25x normalized earnings offers limited upside, and the balance sheet has been weakened by aggressive buybacks leaving stockholders' equity at just $54M with negative tangible book value of $4.6B. At current levels (~$87, ~40% above 52-week low), new capital faces unfavorable risk/reward; the position is best suited as an income-generating defensive holding for existing shareholders.
Macro: Hawkish Fed pivot: Polymarket shows 96% implied probability of ZERO Fed rate cuts in 2026, first rate hike since 2023 confirmed. Soft landing still priced (8% US recession probability by YE 2026). Geopolitical energy risks elevated: US-Iran war ongoing ($38B cost through Aug 1, +$3B/month), Strait of Hormuz disruption; Saudi Aramco notifying European refiners of zero crude deliveries after Red Sea pipeline attack; Russia-Ukraine exchanged drone strikes hitting Moscow oil refinery. Trump-Xi summit scheduled Sept 24 — trade/tariff headlines can move EM-exposed multinationals overnight. Sugar prices recovering on Brazil rain delays — modest input-cost tailwind reversal for toothpaste/Sorbitol inputs. Higher-for-longer rates create two-edged pressure: dividend yield (~2.4%) more competitive versus bonds, but defensive growth multiples vulnerable to discount rate compression at 24-28x P/E.